Fortress Biotech, Inc.
FBIO
$1.81
-$0.02-1.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.50% | -12.80% | 1.78% | 1.59% | 2.53% |
| Total Other Revenue | -94.86% | -94.88% | 3,268.79% | 5,008.75% | 8,670.72% |
| Total Revenue | -32.11% | -31.76% | 31.51% | 31.68% | 32.48% |
| Cost of Revenue | -51.82% | -40.32% | -47.83% | -43.82% | -31.70% |
| Gross Profit | 110.22% | 56.61% | 100.42% | 89.78% | 71.95% |
| SG&A Expenses | 13.94% | -4.45% | -22.69% | -28.95% | -28.64% |
| Depreciation & Amortization | -2.01% | 12.50% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.37% | -27.20% | -36.22% | -36.28% | -28.82% |
| Operating Income | 22.07% | 24.37% | 57.94% | 56.47% | 47.13% |
| Income Before Tax | 22.83% | 21.60% | 32.38% | 52.32% | 37.25% |
| Income Tax Expenses | -22.12% | -22.12% | -24.07% | 15.81% | 15.81% |
| Earnings from Continuing Operations | 22.83% | 21.60% | 32.36% | 52.19% | 37.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -21.74% | -19.95% | -28.08% | -48.24% | -34.36% |
| Net Income | 24.49% | 24.14% | 38.05% | 57.51% | 40.97% |
| EBIT | 22.07% | 24.37% | 57.94% | 56.47% | 47.13% |
| EBITDA | 22.40% | 24.32% | 58.82% | 57.21% | 47.75% |
| EPS Basic | 64.92% | 68.11% | 72.11% | 76.53% | 59.07% |
| Normalized Basic EPS | 159.62% | 146.44% | 151.26% | 68.86% | 84.38% |
| EPS Diluted | 64.92% | 68.11% | 72.11% | 76.53% | 59.07% |
| Normalized Diluted EPS | 159.62% | 146.44% | 151.26% | 68.86% | 84.38% |
| Average Basic Shares Outstanding | 111.50% | 150.40% | 137.88% | 105.24% | 73.11% |
| Average Diluted Shares Outstanding | 111.50% | 150.40% | 137.88% | 105.24% | 73.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.67% | 0.34% | -0.21% | -1.35% | -0.69% |